You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 18, 2025

CLINICAL TRIALS PROFILE FOR DESFLURANE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Desflurane

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00212147 ↗ Interaction of Cobalamin Status With Nitrous Oxide in Relation to Postoperative Cognitive Changes in the Elderly Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 2003-09-01 Low cobalamin (vitamin B12) levels are frequent in the elderly. Most often they reflect a mild metabolic abnormality without clinical symptoms (subclinical cobalamin deficiency). It is unclear if these elderly people require medical intervention, unlike that small minority with clinical symptoms which can progress and create severe blood or nervous system problems. The study aims to determine if nitrous oxide (N2O), a common anesthetic agent, worsens cobalamin status in elderly patients with unrecognized subclinical cobalamin deficiency. The reason for concern is that N2O inactivates cobalamin and can aggravate the clinical picture of patients who already have clinical manifestations of cobalamin deficiency. The elderly are known to have an increased risk of developing mental changes after surgery and it may be that sometimes these result from aggravation of subclinical cobalamin deficiency. The study recruits people over the age of 60 years who are undergoing clinically indicated elective surgery requiring general anesthesia for more than 1 hour. Patients meeting exclusion and inclusion criteria are randomized to receive either a standard anesthetic regimen that includes N2O or a nearly identical one without N2O. Before surgery and 2 weeks and 4 weeks after surgery, each patient undergoes (1) a broad battery of tests of cognition and mood and (2) blood tests measuring cobalamin, folate and homocysteine-methionine metabolism to determine whether they have any subtle biochemical impairment of cobalamin status. DNA from blood cells is also tested for the presence of common mutations that affect key enzymes in those metabolic pathways. A brief testing for postoperative delirium is also done 2 hours after surgery. The patient subgroups' are analyzed for neuropsychologic changes over time, using the preoperative test as the baseline for all comparisons, and associations of those changes with metabolic, genetic, demographic and clinical data. The primary question is what effect routine N2O exposure has on the latter compared with non-N2O anesthesia in elderly people who either have or do not have subclinical cobalamin deficiency. It will help answer whether or not the combination can help explain the increased risk of cognitive problems after surgery in elderly patients, and by extension whether preoperative cobalamin testing and treatment may be indicated in the elderly. It will also test whether genetic predisposition affects the described problems.
NCT00219856 ↗ Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy Completed Ministry of Health, France Phase 3 2004-08-01 Propofol is an anaesthetic agent that showed in vitro and in vivo anti oxidant properties. No data are available concerning the potential benefit of a total anaesthesia with propofol in partial hepatic surgery. Patients who undergo partial hepatic resection have frequent liver insufficiency that could be related in part to the oxidative stress induced by clamping the hepatic vessels during the surgical intervention. Our hypothesis is that propofol, by increasing liver resistance to this ischemia-reperfusion phenomenon, could improve the remaining liver function recovery, and therefore could reduce post surgical morbidity. The aim of the study is to evaluate the anti oxidant effects of propofol compared to another widely used anaesthetic agent, inhaled desflurane, during and after partial hepatic resection with hepatic vessels clamping. The primary endpoint will be the level of malondialdehyde (a plasmatic marker of oxidative stress), 30 minutes after the end of hepatic clamping.
NCT00219856 ↗ Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy Completed Rennes University Hospital Phase 3 2004-08-01 Propofol is an anaesthetic agent that showed in vitro and in vivo anti oxidant properties. No data are available concerning the potential benefit of a total anaesthesia with propofol in partial hepatic surgery. Patients who undergo partial hepatic resection have frequent liver insufficiency that could be related in part to the oxidative stress induced by clamping the hepatic vessels during the surgical intervention. Our hypothesis is that propofol, by increasing liver resistance to this ischemia-reperfusion phenomenon, could improve the remaining liver function recovery, and therefore could reduce post surgical morbidity. The aim of the study is to evaluate the anti oxidant effects of propofol compared to another widely used anaesthetic agent, inhaled desflurane, during and after partial hepatic resection with hepatic vessels clamping. The primary endpoint will be the level of malondialdehyde (a plasmatic marker of oxidative stress), 30 minutes after the end of hepatic clamping.
NCT00244283 ↗ A Comparison of Two Anaesthetic Methods of Protecting Heart Tissue During Cardiac Surgery Unknown status European Society for Intravenous Anaesthesia Phase 4 2006-01-01 To compare two different methods of protecting heart muscle from damage caused by a decreased blood supply. Exposure to the anaesthetic agent sevoflurane can allow the heart muscle to resist longer periods of low blood or oxygen supply without sustaining the amount of damage that it would otherwise expect to. The use of thoracic epidural analgesia improves the blood flow to the heart muscle and has also been shown to reduce the amount of damage the heart muscle may otherwise sustain. The aim of this study is to compare these two methods.
NCT00244283 ↗ A Comparison of Two Anaesthetic Methods of Protecting Heart Tissue During Cardiac Surgery Unknown status Golden Jubilee National Hospital Phase 4 2006-01-01 To compare two different methods of protecting heart muscle from damage caused by a decreased blood supply. Exposure to the anaesthetic agent sevoflurane can allow the heart muscle to resist longer periods of low blood or oxygen supply without sustaining the amount of damage that it would otherwise expect to. The use of thoracic epidural analgesia improves the blood flow to the heart muscle and has also been shown to reduce the amount of damage the heart muscle may otherwise sustain. The aim of this study is to compare these two methods.
NCT00244517 ↗ DIAFAX I+II-Effects of Inhalative Anesthetics on Left Ventricular Diastolic Function Terminated University Hospital, Basel, Switzerland Phase 4 2004-06-01 Anaesthetics may impair the diastolic function of the heart, but the importance of this finding for patients has not been sufficiently examined. Specially the effects on diastolic function in patients with diastolic dysfunction has to be determined. The aim of this study is to examine the effect of isoflurane (only part I), sevoflurane and desflurane (part I+II) on the diastolic left ventricular function by doppler echocardiography.
NCT00335972 ↗ The Effects of Dexmedetomidine and Remifentanil on Carotid Patients Terminated The Cleveland Clinic Phase 4 2006-06-01 We propose to test whether intraoperative administration of dexmedetomidine will reduce hemodynamic control in the intra- and post-operative periods and reduces PACU analgesic requirements in patients undergoing carotid endarterectomy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Desflurane

Condition Name

Condition Name for Desflurane
Intervention Trials
Anesthesia 27
Pain, Postoperative 10
Postoperative Pain 8
Obesity 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Desflurane
Intervention Trials
Pain, Postoperative 19
Delirium 10
Emergence Delirium 8
Respiratory Aspiration 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Desflurane

Trials by Country

Trials by Country for Desflurane
Location Trials
Korea, Republic of 51
United States 38
China 38
Turkey 14
Canada 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Desflurane
Location Trials
Ohio 8
New York 7
Illinois 5
Texas 4
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Desflurane

Clinical Trial Phase

Clinical Trial Phase for Desflurane
Clinical Trial Phase Trials
Phase 4 95
Phase 3 11
Phase 2/Phase 3 2
[disabled in preview] 140
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Desflurane
Clinical Trial Phase Trials
Completed 152
Recruiting 35
Unknown status 28
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Desflurane

Sponsor Name

Sponsor Name for Desflurane
Sponsor Trials
Seoul National University Hospital 17
Yonsei University 17
Baxter Healthcare Corporation 12
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Desflurane
Sponsor Trials
Other 329
Industry 16
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Desflurane: Clinical Trials, Market Analysis, and Projections

Introduction to Desflurane

Desflurane is a highly volatile, non-flammable, and non-explosive anesthetic agent widely used in the maintenance of general anesthesia. It is known for its rapid onset and recovery characteristics, making it a preferred choice in various surgical procedures.

Clinical Trials: Desflurane vs. Sevoflurane

Recent clinical trials have compared the efficacy and safety of desflurane versus sevoflurane, another commonly used volatile anesthetic.

Postoperative Recovery

A prospective, observer-blinded, randomized clinical trial involving 190 older adults undergoing minor- to moderate-risk noncardiac surgeries evaluated the effect of desflurane versus sevoflurane on postoperative recovery. The study found no significant difference in the median duration of postoperative recovery between the two groups. Both anesthetics allowed for quick recovery, with a high percentage of patients meeting discharge criteria upon arrival at the post-anesthesia care unit (PACU)[1].

Postoperative Nausea and Vomiting (PONV) and Other Parameters

The same trial also assessed the incidence of PONV, bispectral index (BIS) values, and S100B concentrations. No significant differences were observed in these parameters between the desflurane and sevoflurane groups, indicating that both anesthetics have similar profiles in terms of these outcomes[1].

Cardioprotective Effects

A secondary analysis of the same trial focused on the cardioprotective effects of desflurane versus sevoflurane. The study measured postoperative cardiac biomarkers such as troponin T, NT-proBNP, and copeptin. There were no significant differences in the postoperative maximum concentrations of these biomarkers between the two groups, suggesting that both anesthetics have similar cardioprotective profiles in older adults undergoing low- to moderate-risk noncardiac surgery[4].

Market Analysis

Current Market Size and Growth

The global anesthesia drugs market, which includes desflurane, was valued at USD 5.9 billion in 2023 and is expected to reach USD 8.6 billion by 2032, growing at a CAGR of 4.2% during the forecast period. Desflurane is a significant segment within this market, known for its low risk of nephrotoxicity and quick recovery times compared to other anesthetics[3].

Market Drivers

Several factors are driving the growth of the desflurane market:

  • Increasing Surgical Procedures: The rising number of surgical procedures, particularly among the geriatric population and those with chronic conditions, is a key driver.
  • Advancements in Anesthetic Techniques: Improvements in inhalation anesthetic delivery systems and the development of more efficient and safer anesthetics are boosting market growth.
  • Shift to Ambulatory Surgical Centers: The increasing preference for ambulatory surgical centers due to their cost-effectiveness and convenience is also contributing to the market expansion[5].

Market Segmentation

The desflurane market can be segmented by application, user type, and region:

  • Application: Hospital use, ambulatory services, day surgery, emergency care, inpatient surgeries, and outpatient procedures.
  • User Type: Healthcare professionals, including anesthesiologists.
  • Region: Americas, Asia-Pacific, Europe, Middle East, and Africa[5].

Market Projections

Revenue Growth

The desflurane segment held over USD 255 million in revenue in 2018 and is projected to grow significantly by 2025. This growth is attributed to the advantages offered by desflurane, such as its rapid onset and recovery times, and its low risk of nephrotoxicity compared to other anesthetics[2].

Emerging Trends

  • Sustainable Anesthetic Solutions: There is a growing interest in developing low-global-warming anesthetic solutions and closed-loop delivery systems to minimize environmental impact and enhance precision.
  • Personalized Medicine: The shift towards personalized medicine is creating demand for diverse anesthesia agents, including desflurane.
  • Technological Advancements: Advancements in inhalation anesthetic delivery systems and the development of reusable equipment are expected to drive market growth[5].

Challenges and Opportunities

Challenges

  • Storage and Handling: Desflurane poses technical challenges in terms of storage and handling in clinical settings.
  • Supply Chain Disruptions: Mitigating the risks posed by supply chain disruptions is crucial for maintaining the availability of desflurane.
  • Cost Efficiency: Balancing efficacy with cost reduction in desflurane formulations remains a challenge[5].

Opportunities

  • Expansion in Ambulatory Surgical Centers: The growing preference for ambulatory surgical centers offers significant expansion opportunities for desflurane.
  • Innovations in Delivery Systems: Developing innovative delivery systems that are sustainable and cost-effective can drive market growth.
  • Global Market Penetration: There are opportunities for market penetration in emerging economies with rising healthcare expenditure[5].

Key Takeaways

  • Desflurane and sevoflurane have similar profiles in terms of postoperative recovery, PONV, and cardioprotective effects.
  • The desflurane market is driven by increasing surgical procedures, advancements in anesthetic techniques, and the shift to ambulatory surgical centers.
  • The market is expected to grow significantly, with a focus on sustainable solutions, personalized medicine, and technological advancements.
  • Challenges include storage and handling, supply chain disruptions, and cost efficiency.

FAQs

What are the key advantages of desflurane over other anesthetics?

Desflurane offers rapid onset and recovery times, low risk of nephrotoxicity, and minimal risk of fulminant hepatitis, making it a preferred choice in many surgical procedures.

How does desflurane compare to sevoflurane in clinical trials?

Clinical trials have shown that desflurane and sevoflurane have similar profiles in terms of postoperative recovery, PONV, and cardioprotective effects, making both suitable for same-day discharge in older adults.

What are the market drivers for the desflurane segment?

The market is driven by increasing surgical procedures, advancements in anesthetic techniques, and the shift to ambulatory surgical centers.

What are the challenges facing the desflurane market?

Challenges include technical difficulties in storage and handling, supply chain disruptions, and the need to balance efficacy with cost reduction.

What are the future projections for the desflurane market?

The desflurane market is projected to grow significantly, driven by sustainable solutions, personalized medicine, and technological advancements.

Sources

  1. Desflurane versus sevoflurane anesthesia and postoperative recovery in older adults eligible for same-day discharge. PubMed, 2024.
  2. Inhalation Anesthesia Market 2019-2025 | Global Industry Share. GMI Insights.
  3. Anesthesia Drugs Market Size & Share | Global Trends 2032. SNS Insider.
  4. Desflurane Versus Sevoflurane and Postoperative Cardiac Biomarkers in Older Adults Undergoing Low- to Moderate-Risk Noncardiac Surgery. MDPI, 2024.
  5. Desflurane Market Size & Share 2025-2030. 360iResearch.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.